Back to today’s briefing

Story perspectives

FDA Considers Approval of Controversial Animal-Derived Thyroid Medications

8/17/2025

32 4

Summary

Story summary

The FDA expressed concerns over unapproved animal-derived thyroid medications due to safety risks and inconsistent hormone levels.
In response to public backlash, FDA Commissioner Marty Makary announced potential approval plans, contingent on clinical trial outcomes.
Experts caution that unregulated animal-derived pills may pose health risks, while some doctors support their availability as alternatives.

1 of 1

Story summary

The FDA expressed concerns over unapproved animal-derived thyroid medications due to safety risks and inconsistent hormone levels.
In response to public backlash, FDA Commissioner Marty Makary announced potential approval plans, contingent on clinical trial outcomes.
Experts caution that unregulated animal-derived pills may pose health risks, while some doctors support their availability as alternatives.